Gareth Macdonald

France

Business and Science Writer at Freelance

Featured in:

linkedin.com Favicon

flipboard.com Favicon

thescottishsun.co.uk Favicon

informaconnect.com Favicon

fiercebiotech.com Favicon

genengnews.com Favicon

pmlive.com Favicon

biopharma-reporter.com Favicon

outsourcing-pharma.com Favicon

bioprocessintl.com + 4 more

Articles

UF/DF Effective Against SUT-Derived Impurities

3 days ago | genengnews.com | Gareth Macdonald

Monoclonal antibody (mAb) manufacturers struggling with single-use technology (SUT)-derived impurities should use ultrafiltration and diafiltration as the basis of their removal strategies, according to new research. Single-use technologies provide a low-cost, flexible means of manufacturing biopharmaceuticals that is free of the time-consuming cleaning and validation steps required when using stainless steel culturing systems.
IRT ideal for cell and gene therapy studies, according to IQVIA

4 days ago | informaconnect.com | Gareth Macdonald

Interactive response technologies (IRTs) are an ideal fit for cell and gene therapy trials, according to IQVIA, which says sponsors and CROs increasingly view software suppliers as partners. The health data and research services firm shared its view on IRT last week, arguing in a blog post that such systems are ideal for the unique, highly complex logistical challenges involved in cell and gene therapy (CGT) clinical studies.
AbbVie partners with Sarah Cannon Research Institute to accelerate cancer studies

4 days ago | informaconnect.com | Gareth Macdonald

AbbVie has teamed up with the Sarah Cannon Research Institute to enhance the pace of its cancer drug clinical development programs. The deal will leverage SCRI’s network of 1,300 physicians and 200 locations in 20 US states to “enhance the delivery” of oncology-focused clinical trials. Financial terms were not disclosed.
MHRA says AI can accelerate trials and speed recruitment

4 days ago | informaconnect.com | Gareth Macdonald

AI could accelerate drug development by helping preclinical candidates move into human trials faster, according to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The regulator spoke about the potential benefits of AI this week, citing its efforts to develop predictive computer models of drug studies as an example.
UK backs AI-generated placebo groups to speed drug trials

1 week ago | informaconnect.com | Gareth Macdonald

AI-generated, synthetic clinical trial data has the potential to speed up drug research, according to the UK government. The UK Department for Science, Innovation and Technology (DSIT) made the comments last week, citing a recently completed Medicines and Healthcare products Regulatory Agency (MHRA) project that saw researchers use AI-data in place of a placebo control group as the basis for the idea.
EU industry group says public-private partnerships are optimizing trial sector

1 week ago | informaconnect.com | Gareth Macdonald

Public-private partnerships are optimizing Europe’s clinical trial ecosystem, helping make drug research more diverse and working to attract sponsors and CROs, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Brussels group wrote about how collaborations are impacting drug studies last week, citing the Innovative Health Initiative (IHI) and the Innovative Medicines Initiative (IMI) as examples.
PhRMA-backed Yale trial diversity program launches as nonprofit

1 week ago | informaconnect.com | Gareth Macdonald

A pilot program that helped community sites take part in drug studies has been set up as a nonprofit organization in a bid to expand its network across the US. The Clinical Trials Access Collaborative (CTAC) — which launched last week — was developed by Yale School of Medicine researchers looking to partner with community sites to increase diversity in clinical trials.
Cutting CAR T Costs via Decentralization, Vector-Alternatives, and Artificial Intelligence

1 week ago | genengnews.com | Gareth Macdonald

Home Topics Artificial Intelligence Cutting CAR T Costs via Decentralization, Vector-Alternatives, and Artificial Intelligence Chimeric antigen receptor (CAR) T cell (blue) attacking non-Hodgkin's lymphoma cells (purple). Healthy red (discs) and white (translucent) blood cells are shown in the background, illustration.
NIIMBL Awards Grants to Real-Time Analytics, mAb, and mRNA-Focused Projects

2 weeks ago | genengnews.com | Gareth Macdonald

Home Topics Artificial Intelligence NIIMBL Awards Grants to Real-Time Analytics, mAb, and mRNA-Focused Projects Credit: Traimak_Ivan/Getty Images Credit: Traimak_Ivan/Getty Images A precipitation-based chromatography alternative, a novel viral vector isolation tech, and a glycosylation prediction system are among the projects awarded funding in the latest round of grants issued by U.S. manufacturing institute, NIIMBL.
CROs must embrace AI says PhaseV, following $50m funding round to expand platform

2 weeks ago | informaconnect.com | Gareth Macdonald

CROs should embrace artificial intelligence (AI), or they risk losing clients to rival drug trial contractors, according to Massachusetts-based technology developer PhaseV. The comments come from PhaseV CEO Raviv Pryluk, who told Clinical Insider, “The reality is that CROs who do not embrace AI will fall behind. We are collaborating with more CROs, and the ones not adopting our technology are losing clients to those who do.